Erlotinib (Tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer

Caio M. Rocha-Lima, Luis E. Raez

Research output: Contribution to journalReview article

17 Scopus citations


Erlotinib (Tarceva) is a small-molecule, orally dosed, anticancer drug that inhibits the epidermal growth factor receptor. Randomized, controlled clinical studies have demonstrated that erlotinib significantly improved survival in patients with previously treated non-small-cell lung cancer and, in combination with chemotherapy, in patients with untreated pancreatic cancer. In this article, we describe the clinical evidence and value of erlotinib as a therapy for non-small-cell lung cancer and pancreatic cancer and discuss ongoing clinical studies to optimize its use in various settings and to identify appropriate patient populations.

Original languageEnglish (US)
Pages (from-to)554-564
Number of pages11
JournalP and T
Issue number10
StatePublished - Oct 1 2009



  • EGFR mutation
  • Erlotinib
  • Non-small-cell lung cancer
  • Pancreatic cancer

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this